Market Access What the low impact of Humira biosimilars teaches us about d... Almost everyone seems to agree that drug prices are too high.
Views & Analysis Harmonised health technology assessment in Europe? There's a... Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture
Views & Analysis NICE numbers: trends in recommendations should prompt a revi... Should there be a different review of NICE as part of a successor PPRS?
Views & Analysis Balancing cost:benefit in ‘well-treated’ malignancies The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
Views & Analysis Accessing biosimilars: untapped potential in EU and US Though they can reduce the costs of health care, biosimilars still face challenges to access.
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
